Global Genetic disorders Partnering 2010-2017: Deal trends, players and financials
Albany, New York, Feb 10, 2017
"Global
Genetic disorders Partnering 2010-2017: Deal trends, players and
financials"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Genetic Disorders Partnering 2010 to 2017 provides the full
collection of Genetic Disorders disease deals signed between the
worlds pharmaceutical and biotechnology companies since 2010.
Trends
in Genetic Disorders partnering deals
Financial
deal terms for headline, upfront and royalty by stage of development
Genetic
Disorders partnering agreement structure
Genetic
Disorders partnering contract documents
Top
Genetic Disorders deals by value
Most
active Genetic Disorders dealmakers
Most
of the deals included within the report occur when a licensee obtains
a right or an option right to license a licensors product or
technology. More often these days these deals tend to be
multi-component including both a collaborative R&D and a
commercialization of outcomes element.
The
report takes readers through the comprehensive Genetic Disorders
disease deal trends, key players and top deal values allowing the
understanding of how, why and under what terms companies are
currently entering Genetic Disorders deals.
The
report presents financial deal terms values for Genetic Disorders
deals, where available listing by overall headline values, upfront
payments, milestones and royalties enabling readers to analyse and
benchmark the value of current deals.
The
initial chapters of this report provide an orientation of Genetic
Disorders dealmaking trends.
Chapter
1 provides an introduction to the report.
Chapter
2 provides an overview of the trends in Genetic Disorders dealmaking
since 2010 covering trends by year, deal type, stage of development,
technology type and therapeutic indication.
Chapter
3 includes an analysis of financial deal terms covering headline
value, upfront payment, milestone payments and royalty rates.
Chapter
4 provides a review of the leading Genetic Disorders deals since
2010. Deals are listed by headline value. The chapter includes the
top 25 most active Genetic Disorders dealmakers, together with a full
listing of deals to which they are a party. Where the deal has an
agreement contract published at the SEC a link provides online access
to the contract.
Chapter
5 provides comprehensive access to Genetic Disorders deals since 2010
where a deal contract is available, providing the user with direct
access to contracts as filed with the SEC regulatory authorities.
Each deal title links via Weblink to an online version of the deal
record contract document, providing easy access to each contract
document on demand.
Chapter
6 provides a comprehensive directory of all Genetic Disorders
partnering deals by specific Genetic Disorders target announced since
2010. The chapter is organized by specific Genetic Disorders
therapeutic target. Each deal title links via Weblink to an online
version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
In
addition, a comprehensive appendix is provided with each report of
all Genetic Disorders partnering deals signed and announced since
2010. The appendices are organized by company A-Z, stage of
development at signing, deal type (collaborative R&D,
co-promotion, licensing etc) and technology type. Each deal title
links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each
contract document on demand.
The
report also includes numerous tables and figures that illustrate the
trends and activities in Genetic Disorders partnering and dealmaking
since 2010.
In
conclusion, this report provides everything a prospective dealmaker
needs to know about partnering in the research, development and
commercialization of Genetic Disorders technologies and products.
–
Report
scope
Global
Genetic Disorders Partnering 2010 to 2017 is intended to provide the
reader with an in-depth understanding and access to Genetic Disorders
trends and structure of deals entered into by leading companies
worldwide.
–
Global
Genetic Disorders Partnering 2010 to 2017 includes:
Trends
in Genetic Disorders dealmaking in the biopharma industry since 2010
Analysis
of Genetic Disorders deal structure
Access
to headline, upfront, milestone and royalty data
Access
to hundreds of Genetic Disorders deal contract documents
Comprehensive
access to over 3500 Genetic Disorders deal records
The
leading Genetic Disorders deals by value since 2010
Most
active Genetic Disorders dealmakers since 2010
Comments
Post a Comment